Latest Breaking News On - Travere filspari - Page 1 : comparemela.com

Novartis rides IgAN trioka to 2 trial wins in rare kidney diseases

Novartis is eyeing an FDA filing for a second drug in immunoglobulin A nephropathy (IgAN), as the Swiss pharma goes all-in on the rare autoimmune kidney disease from three different angles.

US Nephrologists Embrace Current IgA Nephropathy Therapies, Yet a Thriving Pipeline Signals Fierce Market Evolution Ahead

US Nephrologists Embrace Current IgA Nephropathy Therapies, Yet a Thriving Pipeline Signals Fierce Market Evolution Ahead

US Nephrologists Embrace Current IgA Nephropathy Therapies, Yet a Thriving Pipeline Signals Fierce Market Evolution Ahead

Exton, Pennsylvania, Oct. 13, 2023 (GLOBE NEWSWIRE) The FDA's recent approvals of Calliditas' Tarpeyo (budesonide) and Travere's Filspari (sparsentan) to treat primary IgA nephropathy (IgAN) have

EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug - Travere Therapeutics (NASDAQ:TVTX), Calliditas Therapeutics (NASDAQ:CALT), SPDR Series Trust SPDR S&P Biotech ETF (ARCA:XBI)

Calliditas, a rare disease company focused on kidney ailments, is optimistic of its lead drug taking off in a big way.